OXNARD, Calif., March 27, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”) or (the “company”), a leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities (NCEs), today announces it will be exhibiting at the 8th Global Drug Delivery & Formulation (DDF) Summit in Berlin, Germany March 27-29, 2017.
“The DDF Summit is among the most prestigious international conferences related to drug formulation and development,” said Rob Davidson, CEO of CURE Pharmaceutical. “We are anxious to share expertise among this elite group of investigators and manufacturers and look forward to potential future developments emanating from this conference.”
About CURE Pharmaceutical
Headquartered in Oxnard, CA, CURE Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules that it develops and manufactures in its state of the art cGMP facility. CURE leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics. Cure partners with pharmaceutical and biotech companies looking for new methods to deliver their proprietary molecules. The technology enables differentiation within large therapeutic categories and potentially improves patient compliance while widening the therapeutic index. CURE Pharmaceutical is traded under the symbol CURR. For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
About The 8th Global Drug Development & Formulation Summit
The growth of biopharma and patient compliance issues have encouraged us to adopt a drug delivery mindset from discovery right through to production. The host of resulting challenges is being tackled by some of the greatest minds in pharma, academia and technology. Every year we see innovation and breakthroughs at every level of drug development. The DDF Summit brings these inspirational stories to you. Through exclusive case studies, brand new results and in depth analysis you’ll be at the very forefront of modern pharmaceutical development.
The summit features 3 dedicated streams and 60 speakers across 3 days. You’ll find new technologies, concepts and contacts to help you in areas such as:
- Oral delivery of biologics – bioavailability, modeling and innovative drug delivery systems
- Injectability of highly concentrated protein formulations
- Understanding and control of amorphous solid dispersions
- Nanoparticles – preparation, progress and future potential
- Challenges of pediatric drug delivery
- Microneedles and the latest transdermal delivery systems
Complementing the technical streamed sessions, you’ll also have keynotes from industry giants on the bigger picture of where the industry is going. As well as academic and regulatory gurus guiding you through current approval process mine fields. It’s this combination of industry and academic minds with common interests and goals that provide such a richly stimulating and exciting environment.
Forward-looking statements
This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 [email protected]


Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 



